Drug Profile
Lexipafant ophthalmic - InSite Vision
Alternative Names: ISV 611; Lexipafant - InSite VisionLatest Information Update: 31 May 2007
Price :
$50
*
At a glance
- Originator British Biotech
- Developer InSite Vision
- Class Branched-chain amino acids; Eye disorder therapies; Imidazoles; Small molecules
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic conjunctivitis
Most Recent Events
- 08 Jan 2001 No-Development-Reported for Allergic conjunctivitis in USA (Ophthalmic)
- 30 Dec 1997 Phase-II clinical trials for Allergic conjunctivitis in USA (Ophthalmic)
- 01 Sep 1997 Phase-I clinical trials for Allergic conjunctivitis in USA (Ophthalmic)